achieved non-inferior clinical remission at Week 26 and superior sustained clinical remission at Week 52 vs a GC-based regimen1*
resulted in a lower absolute risk of relapse vs a GC-based regimen over 52 weeks1
demonstrated sustained improvement in renal function over 1 year vs a GC-based regimen1
allowed physicians to reduce GC use with a significant reduction in GC toxicity vs a GC-based regimen1,5
demonstrated significant improvements in physical and health-related domains of QoL vs a GC-based regimen1,6†‡
includes TAVNEOS taken as a fixed oral dose2
TAVNEOS demonstrated an acceptable safety profile1,7
TAVNEOS is the first targeted treatment for GPA/MPA recognised by EULAR and KDIGO3,4,8,9